Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TIE2, also known as TEK or CD202B, is a receptor tyrosine kinase primarily expressed on endothelial cells. It serves as a key regulator of angiogenesis, vascular maturation, and endothelial cell survival. It is activated by Angiopoietin-1 (ANGPT1) and modulated by Angiopoietin-2 (ANGPT2). Its dysregulation is implicated in various diseases involving abnormal vessel growth/leakage, including cancer and retinal diseases. Therapeutic strategies are being explored to modulate the Tie2 pathway for treating these disorders.
Modulation of Tie2 pathway to inhibit abnormal vessel growth/leakage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiopoietin-Related Protein Tyrosine Kinase 2 (TIE2).